Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-05-31

Study Completion Date

2009-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine if the maximum tolerated doses of AZD2171, in combination with AZD0530, in treating patients with advanced solid tumours are safe, tolerable and efficacious.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

NCT00502060

Advanced Tumor

COMPLETED PHASE1

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

NCT00750841

Solid Tumors

ACTIVE_NOT_RECRUITING PHASE1

Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases

NCT00501605

Advanced Solid Tumor Liver Metastases

COMPLETED PHASE1

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

NCT04999969

Locally Advanced or Metastatic Solid Tumours

ACTIVE_NOT_RECRUITING PHASE2

A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors

NCT00502567

Advanced Solid Tumor

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

AZD2171 Monotherapy

Group Type EXPERIMENTAL

AZD2171

Intervention Type DRUG

oral tablet multiple ascending doses 20, 30 or 45 mg

2

AZD2171 + AZD0530

Group Type EXPERIMENTAL

AZD2171

Intervention Type DRUG

oral tablet multiple ascending doses 20, 30 or 45 mg

AZD0530

Intervention Type DRUG

oral tablet multiple ascending doses 125 mg or 175 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD2171

oral tablet multiple ascending doses 20, 30 or 45 mg

Intervention Type DRUG

AZD0530

oral tablet multiple ascending doses 125 mg or 175 mg

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

cediranib RECENTIN™

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written consent
* Cancer diagnosis \& stage
* Patients for whom no standard therapy exists
* World Health Organization (WHO) performance status 0-2
* One or more measurable lesions

Exclusion Criteria

* Prostate cancer
* Untreated unstable brain or meningeal metastases
* Specific laboratory ranges
* Pregnant or breast-feeding women
* Any evidence of severe or uncontrolled diseases
* Participation in other trials within 30 days

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No